The influence of genotype on disease severity and concomitant diseases in familial Mediterranean fever patients.

The influence of genotype on disease severity and concomitant diseases in familial Mediterranean fever patients. Clin Exp Rheumatol. 2019 Oct 10; Authors: Aktaş A, Karadavut M, Cansu DÜ, Korkmaz C Abstract OBJECTIVES: To evaluate differences between the patients with familial Mediterranean fever (FMF) with homozygous (Hom), heterozygous (Het) and compound heterozygous (cHet) MEFV mutations in terms of clinical features and severity of the disease, as well as frequency of concomitant disorders, without focusing on Exon 10 mutations. METHODS: The patients with FMF were diagnosed using the Tel-Hashomer diagnostic criteria. The presence of MEFV mutations was investigated in exons 2,3,5 and 10 by multiplex-PCR reverse hybridisation method. All the patients were questioned for the presence of concurrent disorders, and the medical records of these patients were revised retrospectively. RESULTS: 259 unrelated patients (female: 143, male: 116; mean age: 33.5±12 years) were included in this study. Hom and Het mutations were found in 79 (31.9%) and 88 (35.6%) patients with FMF, respectively. cHet mutations were found in 68 (27.5%) FMF patients. Early onset and early diagnosis of FMF were found in Hom group compared to Het and compound Het groups. The number of the patients with a higher severity score was significantly higher in Hom group (n=40, 50.6%) than Het (n=12, 13.6%) and cHet groups (n=10, 14.7%), (p
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Related Links:

Epileptic activity without visible convulsions is common in Alzheimer's disease (AD) and may contribute adversely to the disease progress and symptoms. Transgenic mice with amyloid plaque pathology also display epileptic seizures, but those are too infrequent to assess the effect of anti-epileptic treatments. Besides spontaneous seizures, these mice also display frequent epileptic spiking in epidural EEG recordings, and these have provided a means to test potential drug treatment to AD-related epilepsy. However, the origin of EEG spikes in transgenic AD model mice has remained elusive, which makes it difficult to relate el...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Patients with multiple myeloma (MM) are known to be immune incompetent and experience higher incidences of infectious diseases. However, infective endocarditis (IE) is rarely observed in patients with MM and Morg...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Case report Source Type: research
Publication date: Available online 9 November 2019Source: Journal of Molecular BiologyAuthor(s): Tyler M. Marcinko, Chungwen Liang, Sergey Savinov, Jianhen Chen, Richard W. VachetAbstractIn dialysis patients, the protein β2-microglobulin (β2m) forms amyloid fibrils in a condition known as dialysis-related amyloidosis. To understand the early stages of the amyloid assembly process, we have used native electrospray ionization (ESI) together with ion mobility mass spectrometry (IM-MS) to study soluble pre-amyloid oligomers. ESI-IM-MS reveals the presence of multiple conformers for the dimer, tetramer, and hexamer th...
Source: Journal of Molecular Biology - Category: Molecular Biology Source Type: research
Kidney disease is a serious manifestation of systemic amyloidosis and a major cause of morbidity and mortality. Tuberculosis (TB) occurs up to 27 times more commonly in human immunodeficiency virus (HIV) infec...
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
ConclusionsIn summary, CyBorD showed a ≥VGPR rate of 53% with 26.5% achieving CR, which is similar to that seen in previous studies. In addition, MRD negativity assessed by MPF in patients with CR resulted in no difference on survival outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Sánchez López JD, Rodríguez Ruiz JA, Martínez-Sahuquillo Rico A PMID: 31694764 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
CONCLUSIONS.—: In patients with amyloidosis, determination of the responsible protein is critical for appropriate patient care. In large subspecialty practices and reference laboratories with experience in using and analyzing relevant immunohistochemistry, most amyloid proteins can be identified with an organ-specific algorithm. Referring to an organ-based algorithm may be helpful in providing clinicians with a more specific differential diagnosis regarding amyloid type to help guide clinical evaluation and treatment. When the protein cannot be characterized, mass spectrometry can be performed to definitively classif...
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
AbstractIn 2018, patisiran was the first-ever RNA interference (RNAi)-based drug approved by the US Food and Drug Administration. Now pharmacology textbooks may include a new drug class that  results in the effect first described by Fire and Mello 2 decades ago: post-transcriptional gene silencing by a small-interfering RNA (siRNA). Patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) present with mutations in the transthyretin (TTR) gene that lead to the formation of amyloid deposits in peripheral nerves and heart. The disease may also affect the eye and central nervous system. Th...
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) is an effective regimen for the treatment of patients with newly diagnosed AL amyloidosis however, it remains inadequate to enhance outcomes in high risk groups and minimal information is available on the impact of minimal residual disease (MRD) in overall survival. Hematological and Organ Response was assessed in newly diagnosed AL amyloidosis treated with CyBorD. Results showed a ≥VGPR rate of 53% with 26.5% achieving CR. In addition, MRD negativity assessed by MPF in patients with CR resulted in no difference on survival outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Condition:   Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Interventions:   Drug: Vutrisiran;   Drug: Sterile Normal Saline (0.9% NaCl) Sponsor:   Alnylam Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Amyloidosis | Rheumatology | Study